Evidence map›Paper›PMID 34353373›Full record

ArticleAddiction science & clinical practice2021

Racial/ethnic equity in substance use treatment research: the way forward.

Kathleen Burlew, Caravella McCuistian, José Szapocznik

Abstract readLetter
In one paragraph

Article in Addiction science & clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Participant diversity in ACER: 2010-2022.Alcohol, clinical & experimental research · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kathleen BurlewDepartment of Psychology, University of Cincinnati, Mail Location #210375, Cincinnati, OH, 45213, USA. Kathy.burlew@uc.edu.ORCID 0000-0001-8539-1298
Caravella McCuistianPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA, 94118, USA.
José SzapocznikDepartment of Public Health Sciences, University of Miami Miller School of Medicine, 3380 Devon Road, Miami, FL, 33133-5902, USA.

Funding

The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Substance Use Disorders Treatment/Services Research Training ProgramT32DA007250 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre, Janice Y Tsoh · 1991 to 2026
$7.4M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
NIDA NIH HHS T32 DA007250NIDA NIH HHS T32 DA037801NIDA NIH HHS UG1 DA013720
6 · The paper itself

Abstract

backgroundOpioid use and opioid-related overdose continue to rise among racial/ethnic minorities. Social determinants of health negatively impact these communities, possibly resulting in poorer treatment outcomes. Research is needed to investigate how to overcome the disproportionate and deleterious impact of social determinants of health on treatment entry, retention, drug use and related outcomes among racial/ethnic minorities. The current commentary provides recommendations that may help researchers respond more effectively to reducing health disparities in substance use treatment. We begin with recommendations of best research practices (e.g., ensuring adequate recruitment of racial/ethnic minorities in research, central components of valid analysis, and adequate methods for assessing effect sizes for racial/ethnic minorities). Then, we propose that more NIDA research focuses on issues disproportionately affecting racial/ethnic minorities. Next, techniques for increasing the number of underrepresented racial/ethnic treatment researchers are suggested. We then recommend methods for infusing racial/ethnic expertise onto funding decision panels. This commentary ends with a case study that features NIDA's National Drug Abuse Treatment Clinical Trials Network (CTN).

conclusionsThe proposed recommendations can serve as guidelines for substance use research funders to promote research that has the potential to reduce racial/ethnic disparities in substance use treatment and to increase training opportunities for racial/ethnic minority researchers.

Indexed as

EthnicitySubstance-Related DisordersHumansMinority GroupsRacial GroupsDrug treatmentRacial/ethnic disparitiesRacial/ethnic investigator trainingRacial/ethnic minoritiesThe National Drug Abuse Treatment Clinical Trials Network (CTN)

Identifiers

PMID34353373
PMCPMC8340520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.